Construction and preparation of double-target chimeric antigen receptor T (CAR-T) of FLT3-NKG2D

Abstract

The invention discloses construction and preparation of double-target chimeric antigen receptor T (CAR-T) of FLT3-NKG2D. CAR of the invention belongs to double-target second-generation CAR, and has the functions of overcoming tumor immune escape and enhancing the specific recognition and killing of tumor cells. By combination of the double-target CAR-T and gilteritinib, the treatment dilemma of refractory acute myeloid leukemia of FLT3<mut+> can be effectively solved, and a new treatment strategy is provided for treatment of acute myeloid leukemia.

Description

technical field [0001] The invention relates to the field of biological immune cell therapy, in particular to the construction and preparation of FLT3-NKG2D dual-target CAR-T. Background technique [0002] In 2012, the annual meeting of the International Society for Cell Therapy pointed out that biological immune cell therapy has become the fourth means of tumor treatment besides surgery, radiotherapy, and chemotherapy, and will become a must-have means for future tumor treatment. Immune cell therapy is to collect peripheral venous blood from patients, isolate peripheral blood mononuclear cells in a GMP laboratory, and induce a large number of immune effector cells with high anti-tumor activity under the induction of various cytokines, and then through vein, intradermal Injection, intervention, etc. are reinfused into the patient's body to achieve the purpose of enhancing the patient's immune function and killing tumor cells. Commonly used immune cell therapy methods include...

AI Technical Summary

Problems solved by technology

[0004] At present, most CAR-T cell designs are mainly aimed at lymphocytic leukemia such as CD19-CAR T cells. Single-target CAR-T cells are not effective enough to kill tumors, and super large doses of CAR-T cells are likely to cause serious complications. e.g. cytokine release syndrome (CRS)

Moreover, single-target CAR-T cell therapy is prone to loss of target antigen, leading to tumor recurrence after CAR-T cell therapy

[0005] Secondly, currently most FLT3 inhibitor monotherapy and single CAR-T cell therapy do not significantly improve the OS (overall survival time) of acute myeloid leukemia. For refractory FLT3 mut+ -AML did not produce a significant effect, and there is generally a lack of new anti-leukemia immune mechanisms with clinical therapeutic transformation significance to provide FLT3 mut+ -Treatment for AML patients brings new hope

Images